Cellectar Biosciences Management

How has Jim Caruso's remuneration changed compared to Cellectar Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$51m
Dec 31 2023	US$2m	US$600k	-US$38m
Sep 30 2023	n/a	n/a	-US$38m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$569k	-US$29m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$2m	US$523k	-US$24m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$1m	US$475k	-US$15m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$934k	US$451k	-US$14m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$16m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$770k	US$425k	-US$15m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$16m
Dec 31 2017	US$994k	US$410k	-US$15m

Compensation vs Market: Jim's total compensation ($USD1.97M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Caruso (65 yo)

9yrs

Tenure

US$1,965,140

Compensation

Mr. James V. Caruso, also known as Jim, has been the Chief Executive Officer and President of Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso served as the Chief Commercial Officer and Executiv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Caruso	President	9yrs	US$1.97m	0.14% $ 163.9k
Chad Kolean	VP, CFO & Secretary	2.3yrs	US$1.11m	0.12% $ 141.8k
Jarrod Longcor	Chief Operating Officer	2.3yrs	US$1.36m	0.15% $ 177.0k
Darrell Lea	Chief Commercial Officer	1.6yrs	no data	0.11% $ 131.9k
Andrei Shustov	Senior Vice President of Medical	1.3yrs	no data	0.15% $ 183.3k

2.3yrs

Average Tenure

52yo

Average Age

Experienced Management: CLRB's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Caruso	President	9yrs	US$1.97m	0.14% $ 163.9k
John Neis	Independent Director	16.3yrs	US$93.25k	0.017% $ 20.8k
Frederick Driscoll	Independent Director	7.2yrs	US$93.25k	0.0054% $ 6.5k
Stefan Loren	Independent Director	9yrs	US$93.25k	0% $ 0
Douglas Swirsky	Independent Chairman of the Board	7.2yrs	US$109.88k	0.0070% $ 8.3k
Asher Chanan-Khan	Independent Director	3yrs	US$48.25k	0% $ 0

8.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: CLRB's board of directors are considered experienced (8.1 years average tenure).

Cellectar Biosciences Management

Management criteria checks 2/4

Key information

Recent management updates

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

High number of new directors

Recent updates

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

Price target increased by 23% to US$14.75

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

Price target decreased by 7.7% to US$12.00

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

New minor risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute

Price target decreased to US$12.60

Price target decreased to US$33.63

Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding

Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19

Price target decreased to US$39.38

Cellectar announces reverse stock split

Price target increased to US$5.88

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer

Price target decreased to US$5.38

High number of new directors

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

Cellectar Biosciences EPS beats by $0.03

Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles'

New 90-day low: US$1.74

Cellectar Biosciences, Inc. Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Cellectar Biosciences, Inc. announced that it has received $20.5065 million in funding

Cellectar Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $24.499984 million.

Cellectar Biosciences, Inc. announced that it expects to receive $20.5 million in funding

Cellectar Bio readies stock offering

New 90-day high: US$2.66

New 90-day high: US$1.52

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Cellectar Biosciences EPS beats by $0.05

Cellectar Biosciences, Inc. Announces CLR 131 Has Demonstrated Preliminary Activity in Inoperable Brain Tumors in Phase 1 Study